Catalog No. | HF990026 |
---|---|
Species reactivity | Human |
Applications | Research Grade Biosimilar |
Isotype | Recombinant human Insulin analogue |
Expression system | Mammalian Cells |
Target | INS, Insulin |
Endotoxin level | Please contact the lab for this information. |
Purity | >95% purity as determined by SDS-PAGE. |
Purification | Purified by nickel column chromatography. |
Accession | P01308 |
Form | Liquid |
Storage buffer | 0.01M PBS,pH7.4. |
Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Background | Insulin aspart, sold under the brand name Novolog, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. It is generally used by injection under the skin (into the abdomen, buttocks, thighs, or upper arms) but may also be used by injection into a vein. Maximum effect occurs after about 1–3 hours and lasts for 3–5 hours. Generally a longer-acting insulin like insulin NPH is also needed.Common side effects include low blood sugar, allergic reactions, itchiness, and pain at the site of injection. Other serious side effects may include low blood potassium. Use in pregnancy and breastfeeding is generally safe. It works the same as human insulin by increasing the amount of glucose that tissues take in and decreasing the amount of glucose made by the liver. It is a manufactured form of human insulin; where a single amino acid has been changed, specifically a proline with an aspartic acid at the B28 position.Insulin aspart was approved for medical use in the United States in 2000. In 2022, it was the 76th most commonly prescribed medication in the United States, with more than 8 million prescriptions. Manufacturing involves yeast, which have had the gene for insulin aspart put into their genome. This yeast then makes the insulin, which is harvested from the bioreactor.Medical usesInsulin aspart is indicated to improve glycemic control in people with diabetes.Onset of actionThe onset of action is approximately fifteen minutes, the peak action is reached in 45–90 minutes, and the duration is 3–5 hours.Side effectsThe safety of insulin aspart in people with diabetes is no different from that of regular insulin. The side effects that are commonly associated with insulin therapy include: allergic reactions, injection site irritation, rashes, and hypoglycemia.ref name= |
Note | For research use only. Not for use in clinical or therapeutic applications. |
+33(0)3 90 20 54 70
19 rue de la Haye 67300 Schiltigheim France